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The COVID-19 pandemic is ongoing and spreading, 
affecting individuals in over 200 countries now. While 
COVID-19-related articles are being published every day, 
including guidelines of optimal clinical management [1], 
there are several practical issues that we wished we had 
known earlier. This viewpoint addresses 10 points that 
may be of interest both the logistics, as well as actual 
clinical care of critically ill COVID-19 patients. We stay 
away from items that are self-evident and will not address 
aspects of treatment that are explicitly described else-
where [1]. 
 1. Crisis management in the ICU and planning to surge 
capacity
  It cannot be stressed enough to prepare and antici-
pate [2–5]. Discuss logistics of upscaling the number 
of ICU beds and necessary resources (both equip-
ment and personnel) required to treat these patients 
as early as possible, as both will become limited. 
There needs to be alignment with the hospital board 
of directors about allocation of resources, as short-
age of ICU nurses means that healthcare providers 
working in the operation room and anesthesiology 
department are needed in the ICU, implying that 
other (non-urgent, elective) tasks need to be down-
scaled or stopped. (Risk of ) shortage of personal 
protective equipment imposes a huge psychologi-
cal pressure on medical staff and updates should be 
communicated transparently.
 2. Personnel management
  Start training residents, non-ICU nurses in advance 
[2]. Apart from ICU-related matters that non-ICU 
personal need to become familiar with, adherence 
to infection control precautions is paramount. Also, 
a clear policy to allow/not allow healthcare provid-
ers with a medical history that may increase their 
vulnerability to COVID-19 to work in the COVID-
unit should be communicated. Personnel will be 
confronted with moral dilemmas and may experi-
ence fear and anxiety that deserves attention. Peer-
support and moral deliberation meetings help. Care-
providers are extremely motivated and want to work 
hard, but, if feasible, try to facilitate days-off as well. 
Intensivists should act as leaders and therefore del-
egate as much as possible: ‘Everything someone 
else can do as well should not be done by you.’ For 
example, ask competent colleagues to take care of 
patient transport, vascular access, intubations [2–5]. 
In some settings, an ‘airway team’ or ‘vascular access 
team’ may tremendously facilitate intensivists.
 3. The value of conventional biomarkers
  Generally speaking, patients come in with a high 
CRP and low PCT. Over the days, typically CRP 
decreases, while short-lived increases in PCT may 
be observed that appear not to relate to bacterial 
infection [6]. There is highly fluctuating fever. Typi-
cally, patients that can be extubated ‘early’ (after 
approximately 10  days) show decreasing CRP and 
temperature kinetics. Presentation with a bacterial 
or opportunistic co-infection appears to be uncom-
mon. However, if a co-infection is suspected, e.g., 
because of progressive shock or multiple organ fail-
ure, empirical therapy using antibiotics with activity 
against both typical and atypical respiratory patho-
gens should be considered. Cytokine elevation pro-
files appear reminiscent of secondary hemophago-
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cytic lymphohistiocytosis (HLH), or macrophage 
activation syndrome (MAS). However, while fer-
ritin values are clearly elevated, in the vast majority 
of patients, this is less than one would observe dur-
ing MAS. D-dimer values may reach extremely high 
levels, and hypercoagulation is discussed in the next 
paragraph.
 4. The hidden problem: hypercoagulation and thrombo-
sis
  There is a high incidence of thrombosis and pulmo-
nary embolism [7–9]. In accordance, for patients 
on renal replacement therapy, the lifespan of filters 
appears to be much shorter compared to bacte-
rial sepsis patients with AKI. There should be a low 
threshold to scan for pulmonary embolism, espe-
cially in patients that show a rapid and significant 
increase in their D-dimer level or a sudden increase 
in dead-space ventilation. Also, a spontaneous pro-
longation of the prothrombin or activated partial 
thromboplastin time appears to be a predictor of 
thrombotic complications [8]. Massive pulmo-
nary embolism with acute circulatory arrest may 
be the first presentation of COVID-19. Some have 
advocated to use therapeutic anticoagulation in all 
patients, but this is clearly not without risks. Physi-
cians should be vigilant as cerebral bleeding follow-
ing anticoagulation may occur [10]. Doubling the 
thrombo-prophylactic dose in COVID-19 patients 
could be considered.
 5. Cardiac involvement
  Most COVID-19 patients display only mild hemo-
dynamic instability. However, especially patients 
with preexistent cardiovascular disease are prone to 
hemodynamic decompensation. In addition to acute 
coronary syndrome, fulminant myocarditis may 
occur, with reduced systolic function, accounting for 
a large percentage of early deaths [11, 12]. Overall 
mortality is significantly higher in individuals with 
high TnT compared to those with normal TnT lev-
els. However, severe pulmonary hypertension is not 
frequently present in the early phase of acute respira-
tory failure.
 6. Pharmacological treatment
  Antiviral, immunomodulating and other compounds 
with possible therapeutic efficacy are discussed else-
where [1]. So far, no specific treatment has shown 
clinical benefit. Use of unproven therapies requires 
informed consent and clearly also carries risks that 
should be discussed with the patient/family [13], 
while desperation may drive physicians to try thera-
pies that are backed by little or no evidence. The dif-
ficult choice between this urge to treat (‘just-do-it 
option’) and the urgent need to generate knowledge 
on what actually works (‘must-learn-option’) is clear, 
but there are ways to blend these options [14]. The 
use of steroids during refractory shock is advocated 
[1], but this rarely occurs. Apart from this indication, 
later during the course some patients show a decrease 
in lung compliance in combination with high dead-
space ventilation, suspect for development of fibrosis. 
As in other cases of ARDS, one may consider steroids 
in this subgroup of patients as well [15]
 7. Mechanical ventilation
  Endotracheal intubation is indicated for the usual 
thresholds. Both HFNO and NIV may be tried, but 
patients that are unable to decrease their respiratory 
drive as measured by esophageal pressure have a very 
high risk for failure [16]. Considering mechanical ven-
tilation, one size does not fit all. COVID-19 patients 
may present with divergent pathological features 
ranging from the so-called L-type (low elastance, low 
driving pressure) to the H-type (high elastance, high 
driving pressure) [17]. Although the former appears 
to be more prevalent during the initial phase, this may 
change during the course of the disease [18]. Ultra-
sound could help at the bedside in identifying the dif-
ferent patterns [19]. The potential for recruitment for 
the L-type appears to be limited. Mechanical ventila-
tion should be tailored to the mechanical lung prop-
erties. Lower PEEP and prolonged proning in case of 
severe hypoxia should be considered for L-type. The 
H-type may benefit from higher PEEP levels. Follow-
ing the acute phase, pressure support mode is feasi-
ble in prone position. In our opinion this is safe, if an 
excessive respiratory drive is monitored by using P0.1, 
Pmus or transpulmonary pressure. Excessive respira-
tory drive may result in ‘patient-self-inflicted lung 
injury’ (P-SILI) and explain the transition from the L- 
to the H-type [17].
 8. The thing nobody wants to think about
  It is extremely important that a triage decision sys-
tem is agreed upon before an overwhelming number 
of critically ill patients flood ICU capacity and addi-
tional resources [20]. Deciding between two patients 
that under normal circumstances would both receive 
critical care treatment will pose an immense burden 
on those involved in decision making. We think that 
a triage decision team including intensivists, geri-
atricians, ethicists, nurses and lawyers should opera-
tionalize guidelines issued by a national Critical Care 
Society, achieve consensus with different medical 
specialists, nursing organizations and patient rep-
resentatives and prepare the hospital for this worst-
case scenario. Full immunity from prosecution and 
moral support for those involved are essential com-
ponents of this process.
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 9. Management of the tsunami of research ideas, email 
spamming and info-overload
  Clearly, intensive care physicians should be sure to 
keep informed of the evolving knowledge related 
to new insights into the new disease and its treat-
ment [21], while at the same time, huge logistic chal-
lenges (that are extremely time-consuming) present 
themselves. National societies could play a role in 
providing cyclic updates in guidelines or establish 
a committee that selects clinically relevant papers 
and distribute these among their members. For 
research in this specific patient population, the risk 
of a situation like this is that too many sub-optimally 
designed, small (and therefore statistically under-
powered) interventional studies are initiated and we 
may end with no clinically relevant answers. From 
the start of the outbreak, dozens of emails with sug-
gestions for treatments were/will be sent to all of us. 
Central coordination and prioritizing is useful and 
will increase the chances of performing meaningful 
studies [22].
 10. Post-intensive care follow-up
  Post-intensive care follow-up should be organ-
ized early. A large step-down facility is needed 
as the number of tracheostomized patients with 
severe muscular weakness will likely be immense. 
If ignored, discharge from the ICU will not be pos-
sible. We also need to organize nursing homes and 
rehabilitation centers that can facilitate, e.g., care for 
patients with a tracheal cannula. Psychological sup-
port should be offered early on because the lack of 
human contact caused by personal protection cloth-
ing and visitor limitations will likely result in a higher 
incidence of post-traumatic stress disorder, anxi-
ety and depression in COVID-19 patients, as well 
as their families. Longer-term consequences are for 
now largely unknown but will present themselves in 
the near future.
Concluding general remarks
Current times in the ICU are unprecedented. During 
this pandemic, we are learning about a new disease and 
its treatment and optimal support, and knowledge is 
evolving by the day. Logistic challenges are immense 
and time-consuming, and information overload is a 
threat. We wished to provide a summary of our first 
experience with critically ill COVID-19 patients, 10 
TOO LITTLE
• Personnel
• Personal Protective Equipment
• ICU-beds
TOO MUCH




• Value of biomarkers
• Hypercoagulation
• Cardiac involvement





• Nursing homes for 
tracheostomized patients
• Long-term follow-up
Fig. 1 Summary of previously underexposed issues related to COVID-19
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things that in our view were relatively underexposed in 
previous publications (Fig. 1).
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